CTLA4 and myeloid sarcoma: According to this line of research, Lavon and colleagues have analyzed the expression levels of some co-inhibitory receptors, including CTLA-4, in PBMC from healthy controls and patients with untreated MS and they found that the CTLA-4 levels were not statistically significantly different when comparing the two groups [81].